{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:54:42Z","timestamp":1791219282611,"version":"4.1.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite the efficacy of approved severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in preventing severe disease and death, breakthrough infections continue to occur in vaccinated individuals, contributing to further viral mutation and spread. These limitations may be attributable to the poor induction of mucosal immunity by parenteral vaccination. Mucosal adjuvants, such as T-vant, can enhance vaccine-induced immune responses through the generation of antigen-specific antibodies and T cells in the respiratory tract. In this study, we evaluated the protective efficacy of adjuvanted SARS-CoV-2 receptor binding domain (RBD) subunit vaccines administered by homologous and heterologous routes. Immunized mice were challenged with SARS-CoV-2-XBB.1.5 and monitored for weight loss and survival. Lung and nasopharynx tissues were collected at pre-scheduled timepoints to assess viral loads and histopathology. Additionally, vaccine-induced humoral and cell-mediated immune responses were evaluated in the mucosal and systemic compartments. A prime-pull vaccination strategy \u2013 comprising an intramuscular prime immunization with aluminum hydroxide (alum) and CpG-adjuvanted RBD followed by an intranasal boost with T-vant-adjuvanted RBD \u2013 conferred protection against mortality and lung pathology and cleared virus from the nasopharynx by three days post infection. The prime-pull vaccine regimen elicited superior anti-RBD IgA in the bronchoalveolar lavage fluid and nasal washes, when compared to other vaccine groups. Given that much of the global population has already received parenteral SARS-CoV-2 vaccination or has been naturally exposed, a prime-pull approach could leverage pre-existing systemic immunity using a single mucosal boost.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1673460","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:32:00Z","timestamp":1758259920000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Heterologous prime-pull mucosal vaccination with an adjuvanted RBD vaccine elicits robust IgA production and protects against SARS-CoV-2"],"prefix":"10.3389","volume":"16","author":[{"given":"Allyson H.","family":"Hirsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calder R.","family":"Ellsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatan","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frania","family":"Ramirez Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syamala Rani","family":"Thimmiraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Maness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Pollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Strych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Hotez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Morici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-coV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","article-title":"A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice","volume":"53","author":"Laczk\u00f3","year":"2020","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2310650","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-coV-2 vaccine\u2013induced immunity","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"11467","DOI":"10.1038\/s41598-024-61922-6","article-title":"Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh","volume":"14","author":"Haq","year":"2024","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1038\/s41467-022-31888-y","article-title":"Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults","volume":"13","author":"Kared","year":"2022","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41385-022-00511-0","article-title":"Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection","volume":"15","author":"Sheikh-Mohamed","year":"2022","journal-title":"Mucosal Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00648-4","article-title":"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study","volume":"22","author":"Singanayagam","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.41","article-title":"Secretory IgA\u2019s complex roles in immunity and mucosal homeostasis in the gut","volume":"4","author":"Mantis","year":"2011","journal-title":"Mucosal Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2314808120","article-title":"Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection","volume":"120","author":"Miyamoto","year":"2023","journal-title":"Proc Natl Acad Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1038\/s41467-023-42433-w","article-title":"Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination","volume":"14","author":"Mitsi","year":"2023","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"104893","DOI":"10.1016\/j.ebiom.2023.104893","article-title":"SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses","volume":"98","author":"Puhach","year":"2023","journal-title":"EBioMedicine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/pathogens13020113","article-title":"Mucosal immunity against SARS-coV-2 in the respiratory tract","volume":"13","author":"Noh","year":"2024","journal-title":"Pathogens"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2022.11.016","article-title":"Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses","volume":"31","author":"Morens","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41541-023-00654-6","article-title":"Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities\u2014workshop report","volume":"8","author":"Knisely","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nri1777","article-title":"Mucosal vaccines: the promise and the challenge","volume":"6","author":"Neutra","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101585","article-title":"Next generation mucosal vaccine strategy for respiratory pathogens","volume":"11","author":"Dotiwala","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41541-023-00717-8","article-title":"Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin\u00ae)","volume":"8","author":"Singh","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12916-023-02942-3","article-title":"Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection","volume":"21","author":"Wang","year":"2023","journal-title":"BMC Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5523","article-title":"Thromboembolic events after Ad.26.COV2.S COVID-19 vaccine: Reports to the Vaccine Adverse Event Reporting System","volume":"31","author":"Woo","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1038\/s41467-021-27063-4","article-title":"Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization","volume":"12","author":"Lapuente","year":"2021","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj5305","article-title":"An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice","volume":"14","author":"Nanishi","year":"2022","journal-title":"Sci Transl Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101557","article-title":"A recombinant protein XBB.1.5 RBD\/alum\/cpG vaccine elicits high neutralizing antibody titers against omicron subvariants of SARS-coV-2","volume":"11","author":"Thimmiraju","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.05.007","article-title":"Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern","volume":"40","author":"Pollet","year":"2022","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.03.045","article-title":"Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants","volume":"25","author":"Sokolovska","year":"2007","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.7.11.1731","article-title":"Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy","volume":"7","author":"Barry","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/14760584.2023.2217917","article-title":"From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access","volume":"22","author":"Hotez","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10937400701597766","article-title":"Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide","author":"Krewski","year":"2007","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4499407","DOI":"10.1155\/2023\/4499407","article-title":"Chronic oral administration of aluminum hydroxide stimulates systemic inflammation and redox imbalance in BALB\/c mice","volume":"2023","author":"de Souza","year":"2023","journal-title":"BioMed Res Int"},{"key":"B36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41541-024-00990-1","article-title":"A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis","volume":"9","author":"Galeas-Pena","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/pathogens10050616","article-title":"An outer membrane vesicle-adjuvanted oral vaccine protects against lethal, oral salmonella infection","volume":"10","author":"Harrell","year":"2021","journal-title":"Pathogens"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.10.016","article-title":"Acute respiratory distress in aged, SARS-coV-2-infected african green monkeys but not rhesus macaques","volume":"191","author":"Blair","year":"2021","journal-title":"Am J Pathol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.701278","article-title":"SARS-coV-2 infects endothelial cells in vivo and in vitro","volume":"11","author":"Liu","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1901545","article-title":"SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice","volume":"17","author":"Pollet","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e0289619","DOI":"10.1371\/journal.pone.0289619","article-title":"Determining the statistical significance of the difference between arbitrary curves: A spreadsheet method","volume":"18","author":"Hristova","year":"2023","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00841-7","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway","volume":"7","author":"Willett","year":"2022","journal-title":"Nat Microbiol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898520","article-title":"The cross-protective immunity landscape among different SARS-coV-2 variant RBDs","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01743-x","article-title":"Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection","volume":"25","author":"Ying","year":"2024","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s44298-025-00096-y","article-title":"An XBB.1.5-based inactivated SARS-CoV-2 vaccine partially protects against XBB.1.5 and JN.1 strains in hamsters","volume":"3","author":"Uraki","year":"2025","journal-title":"NPJ Viruses"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abo1303","article-title":"Understanding T cell responses to COVID-19 is essential for informing public health strategies","volume":"7","author":"Vardhana","year":"2022","journal-title":"Sci Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41467-021-21856-3","article-title":"T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses","volume":"12","author":"Ogbe","year":"2021","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adh0687","article-title":"SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19","volume":"8","author":"Cai","year":"2023","journal-title":"Sci Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1107803","article-title":"Defending against SARS-CoV-2: The T cell perspective","volume":"14","author":"Almendro-V\u00e1zquez","year":"2023","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.706902","article-title":"Th2\/th1 cytokine imbalance is associated with higher COVID-19 risk mortality","volume":"12","author":"Pavel","year":"2021","journal-title":"Front Genet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.624483","article-title":"T-helper cell subset response is a determining factor in COVID-19 progression","volume":"11","author":"Gil-Etayo","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.12.024","article-title":"Induction of Th1 and Th2 in the protection against SARS-CoV-2 through mucosal delivery of an adenovirus vaccine expressing an engineered spike protein","volume":"40","author":"Chung","year":"2022","journal-title":"Vaccine"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06951-3","article-title":"Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques","volume":"626","author":"McMahan","year":"2024","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433452","article-title":"Mucosal immunity in COVID-19: a comprehensive review","volume":"15","author":"Alqahtani","year":"2024","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404769101","article-title":"Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection","volume":"101","author":"Messer","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1055457","article-title":"Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications","volume":"14","author":"Abebe","year":"2023","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00390-1","article-title":"Efficacy of SARS-CoV-2 vaccines and the dose\u2013response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials","volume":"4","author":"Yang","year":"2023","journal-title":"Lancet Microbe"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2021.04.061","article-title":"An overview of current COVID-19 vaccine platforms","volume":"19","author":"Nagy","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"7469","DOI":"10.1038\/s41467-024-50376-z","article-title":"Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases","volume":"15","author":"Baden","year":"2024","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2045857","DOI":"10.1080\/21645515.2022.2045857","article-title":"Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review","volume":"18","author":"Nanishi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41541-024-00874-4","article-title":"Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies","volume":"9","author":"Hou","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103344","article-title":"Why does COVID-19 disproportionately affect older people","volume":"12","author":"Mueller","year":"2020","journal-title":"Aging"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41541-023-00800-0","article-title":"An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants","volume":"9","author":"Uraki","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A single-dose intranasal chAd vaccine protects upper and lower respiratory tracts against SARS-coV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"100230","DOI":"10.1016\/j.xcrm.2021.100230","article-title":"A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques","volume":"2","author":"Hassan","year":"2021","journal-title":"Cell Rep Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"109400","DOI":"10.1016\/j.celrep.2021.109400","article-title":"A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters","volume":"36","author":"Bricker","year":"2021","journal-title":"Cell Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh0755","article-title":"Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models","volume":"13","author":"van Doremalen","year":"2021","journal-title":"Sci Transl Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1038\/s41467-021-26178-y","article-title":"ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7","volume":"12","author":"Fischer","year":"2021","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00743-3","article-title":"SARS-CoV-2-specific T cells in infection and vaccination","volume":"18","author":"Bertoletti","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901144","article-title":"Intranasal immunization promotes th17 immune responses","volume":"183","author":"Zygmunt","year":"2009","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e1003875","DOI":"10.1371\/journal.ppat.1003875","article-title":"Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection","volume":"10","author":"Maroof","year":"2014","journal-title":"PloS Pathog"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2020.04.005","article-title":"The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement","volume":"22","author":"Hotez","year":"2020","journal-title":"Microbes Infect"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.24.477597","article-title":"Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses","volume":"378","author":"Mao","year":"2022","journal-title":"Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1673460\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:32:01Z","timestamp":1758259921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1673460\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2025.1673460"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1673460","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"article-number":"1673460"}}